Cambridge, Massachusetts-based gene therapy venture ElevateBio raised a staggering $525 million Series C financing to continue its pursuit of disruptive medicinal models addressing some of…
Two patients with sickle cell disease involved with a gene-based therapy trial now have been diagnosed with cancer, and the clinical trial that is their…
A gene therapy for patients with transfusion-dependent beta thalassemia (TDT) didn’t fare well after a thorough review by the United Kingdom’s National Institute for Health…
A Philadelphia gene-therapy biotech venture just raised $88 million in investment from Johnson & Johnson and other investors, domestic and from Europe, to help accelerate…
Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has led a €20 million Series A financing…
A painful inherited blood disorder affecting millions of people, especially Black people, occurs because of a deficiency of red blood cells to actually carry oxygen…
Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted…
Germany-based Bayer acquired AskBio’s industry leading AAV-based gene therapy platform to accelerate its ability to bring urgently needed treatments to patients across multiple disease areas…
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), positioning itself as a leader in precision genetic medicine for rare diseases, recently announced positive results from the ongoing study…
Picking up on the ongoing “Family Man” saga, in New York Court, EGT claims that Zynteglo, the Bluebird Bio product for Thalassemia, created Clonal Dominance.…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
